Vibrance-1 Study – Patient Worthy

Alkermes’ Alixorexton Shows Promise in Narcolepsy Type 1: Vibrance-1 Phase 2 Results to Be Unveiled at World Sleep 2025

Post author:Bree Clare
Post published:October 23, 2025
Post category:Narcolepsy

Alkermes is set to present detailed positive results from its Vibrance-1 Phase 2 study of alixorexton, a novel, once-daily oral orexin 2 receptor agonist, in patients with narcolepsy type 1…

CLICK HERE TO SHARE YOUR STORY!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More